Genflow Biosciences (GENF) Competitors GBX 0.60 -0.05 (-7.69%) As of 08/22/2025 11:50 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock GENF vs. OBD, BVX, IMM, CIZ, HEMO, EVG, MTFB, DEST, BSFA, and ROQShould you be buying Genflow Biosciences stock or one of its competitors? The main competitors of Genflow Biosciences include Oxford BioDynamics (OBD), BiVictriX Therapeutics (BVX), ImmuPharma (IMM), Cizzle Biotechnology (CIZ), Hemogenyx Pharmaceuticals (HEMO), Evgen Pharma (EVG), Motif Bio (MTFB), Destiny Pharma (DEST), BSF Enterprise (BSFA), and Roquefort Therapeutics (ROQ). These companies are all part of the "biotechnology" industry. Genflow Biosciences vs. Its Competitors Oxford BioDynamics BiVictriX Therapeutics ImmuPharma Cizzle Biotechnology Hemogenyx Pharmaceuticals Evgen Pharma Motif Bio Destiny Pharma BSF Enterprise Roquefort Therapeutics Oxford BioDynamics (LON:OBD) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership. Does the media refer more to OBD or GENF? In the previous week, Oxford BioDynamics' average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score. Company Overall Sentiment Oxford BioDynamics Neutral Genflow Biosciences Neutral Which has stronger valuation and earnings, OBD or GENF? Genflow Biosciences has lower revenue, but higher earnings than Oxford BioDynamics. Genflow Biosciences is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOxford BioDynamics£5.75M1.56-£103.52M-£5.70-0.08Genflow Biosciences-£226.19K-9.04-£1.76M-£0.53-1.13 Do insiders and institutionals believe in OBD or GENF? 44.3% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 9.2% of Genflow Biosciences shares are owned by institutional investors. 16.8% of Oxford BioDynamics shares are owned by company insiders. Comparatively, 64.2% of Genflow Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is OBD or GENF more profitable? Genflow Biosciences has a net margin of 778.46% compared to Oxford BioDynamics' net margin of -1,800.32%. Genflow Biosciences' return on equity of -208.12% beat Oxford BioDynamics' return on equity.Company Net Margins Return on Equity Return on Assets Oxford BioDynamics-1,800.32% -289.38% -56.23% Genflow Biosciences 778.46%-208.12%-58.66% Which has more volatility and risk, OBD or GENF? Oxford BioDynamics has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Genflow Biosciences has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. SummaryGenflow Biosciences beats Oxford BioDynamics on 6 of the 11 factors compared between the two stocks. Get Genflow Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GENF vs. The Competition Export to ExcelMetricGenflow BiosciencesBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£2.05M£137.09M£5.76B£3.22BDividend YieldN/A3.74%4.41%5.04%P/E Ratio-1.133.8731.10164.70Price / Sales-9.044,057.33436.34310,111.41Price / Cash3.0013.1937.7327.93Price / Book2.4246.309.535.91Net Income-£1.76M-£90.99M£3.26B£5.89B7 Day Performance-4.61%0.42%2.10%49.53%1 Month Performance-23.66%3.51%2.81%56.40%1 Year Performance-72.01%205.46%30.56%136.22% Genflow Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GENFGenflow BiosciencesN/AGBX 0.60-7.7%N/A-72.0%£2.05M-£226.19K-1.135High Trading VolumeOBDOxford BioDynamicsN/AGBX 0.44+4.5%N/A-93.3%£8.37M£5.75M-0.0845BVXBiVictriX TherapeuticsN/AN/AN/AN/A£8.25MN/A-250.0017Gap UpHigh Trading VolumeIMMImmuPharmaN/AGBX 1.60+5.3%N/A+17.2%£6.80M-£71.31K-2.7713Gap UpCIZCizzle BiotechnologyN/AGBX 1.38+6.2%N/A-16.1%£5.44MN/A-1,925.764Negative NewsGap DownHEMOHemogenyx PharmaceuticalsN/AGBX 150.38+5.7%N/A+13,300.0%£5.36MN/A-769.2714Gap UpHigh Trading VolumeEVGEvgen PharmaN/AN/AN/AN/A£3.42MN/A-80.0010MTFBMotif BioN/AN/AN/AN/A£3.28MN/A-0.036DESTDestiny PharmaN/AN/AN/AN/A£2.87M£135.03K-50.0024Gap DownHigh Trading VolumeBSFABSF EnterpriseN/AGBX 2.25+11.1%N/A-41.2%£2.78M£80.25K-1.3612Gap UpROQRoquefort TherapeuticsN/AGBX 1.62-1.8%N/A-68.1%£2.06M£2.66K-1.349Gap Down Related Companies and Tools Related Companies OBD Competitors BVX Competitors IMM Competitors CIZ Competitors HEMO Competitors EVG Competitors MTFB Competitors DEST Competitors BSFA Competitors ROQ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:GENF) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genflow Biosciences plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Genflow Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access